Toothaches

Made for my good friend, Alida.
Personal experience: mouthwash rinse with ¼ teaspoon Gromwell, then broke open a 1000mg 10:1 extract capsule or Astragalus and covered the tooth with it. Went from a 6 to a .5 on the pain scale within 60 seconds.

The Synergistic Potential of Astragalus and Gromwell Extracts in Advanced Periodontal Therapy

I. Pathogenesis of Periodontal Disease and Rationale for Phytotherapeutic Intervention

Periodontal disease, encompassing gingivitis and the more destructive periodontitis, represents a global health concern characterized by chronic inflammation resulting from microbial challenge. Effective treatment requires a multifaceted approach that addresses both the causative pathogens and the host's immune response.

Understanding Periodontitis: The Chronic Inflammatory-Microbial Cascade

Periodontitis is defined primarily as an inflammatory disease of the oral cavity leading to the formation of periodontal pockets, the resorption of alveolar bone, and the eventual loosening and loss of teeth.[1] While dental plaque biofilm serves as the primary etiological agent, the resultant tissue destruction is largely mediated by a dysregulated host immune response and the chronic inflammatory environment it generates.[1] Crucially, the effects of periodontitis are not confined to the oral cavity. Recent findings highlight its association with various systemic diseases, including rheumatoid arthritis, type 2 diabetes, atherosclerotic cardiovascular

disease, and osteoporosis, underscoring the necessity of therapeutic interventions that can mitigate systemic inflammatory burden as well as local infection.[1] Current clinical treatments often rely on pharmacological interventions, typically as adjuncts to basic scaling and surgical procedures.[1]

Rationale for Using Astragalus and Gromwell in TCM Context

The investigation into phytotherapeutic agents offers a promising avenue, leveraging centuries of traditional medicine experience coupled with modern mechanistic validation. Traditional Chinese Medicine (TCM) utilizes *Astragalus* (*Astragalus propinquus* or *A. membranaceus*) extensively. In TCM philosophy, Astragalus is known for its sweet taste and warm nature, and is believed to "tonify *qi* and raise *yang*," actions corresponding directly to its modern validated role in modulating and consolidating the body's immune defenses.[1]

The use of complex, multi-component herbal preparations is a foundational principle of TCM and Korean traditional medicine. This approach aims to achieve synergistic effects, whereby the combined action of extracts proves more efficacious than the sum of the individual components.[2] This concept is supported by research indicating that polyherbal formulations have proven effective in managing the complications associated with gingivitis.[3] The inclusion of Astragalus addresses the critical need to modulate the immunological stress associated with chronic periodontitis, complementing purely local treatments. Therefore, incorporating an ingredient like Astragalus, which provides beneficial effects on host immunity and structural preservation, elevates the therapeutic strategy beyond conventional anti-infective or palliative care.

II. Mechanistic Profile of Astragalus (*A. propinquus/membranaceus*) in Periodontitis Management

Astragalus extracts function primarily as potent host-modulating agents. Its rich profile of bioactive constituents—including Astragalus Polysaccharides (APS), flavonoids (such as Quercetin and Kaempferol), and saponins (like Astragaloside IV or ASIV)—targets the core destructive elements of periodontal progression: uncontrolled inflammation and tissue breakdown.[1]

Primary Bioactive Constituents and Anti-inflammatory Efficacy

The root extract of *A. membranaceus* exhibits well-established anti-inflammatory, antioxidant, and immunomodulatory effects.[4] Mechanistic studies demonstrate that the extract significantly mitigates induced inflammatory responses by downregulating both the mRNA expression and the subsequent release of critical pro-inflammatory mediators.[6] Specifically, Astragalus reduces levels of Interleukin-6 (IL-6), Interleukin-1β (IL-1β), and Tumor Necrosis Factor-α (TNF-α) in inflammatory models, including LPS-stimulated macrophages and TNF-α-stimulated human chondrocytes.[6] This profound ability to suppress the production of major inflammatory cytokines is crucial, as these mediators form the destructive inflammatory milieu that drives gingival and periodontal tissue damage.

Modulation of Tissue Degradation and Matrix Metalloproteases (MMPs)

The progression of periodontitis is characterized by the breakdown of the extracellular matrix that supports the teeth, driven by excessive activity of matrix-degrading enzymes. Astragalus directly addresses this by downregulating the expression and release of key Matrix Metalloproteases (MMPs), notably MMP-3 and MMP-13, as well as A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5).[6] Bioinformatics analysis further confirms that MMP-9 is a core potential target for Astragalus's active components in periodontitis treatment.[8] The inhibition of these matrix-degrading enzymes is vital for preserving the structural integrity of the periodontal ligament and cementum, thereby halting the anatomical deterioration inherent to the disease.

The comprehensive nature of Astragalus’s action, which simultaneously addresses inflammation, tissue degradation, and subsequent bone loss, positions it as a sophisticated host-modulating therapy. While other agents may focus only on the microbial trigger, Astragalus attacks the complex consequences of infection, ensuring efficacy against periodontitis, where tissue damage is already established.

Inhibition of Alveolar Bone Resorption (Anti-Osteoclastogenic Action)

Alveolar bone destruction is the definitive pathological marker separating gingivitis from periodontitis. Evidence shows that Astragalus Polysaccharide (APS) provides a confirmed protective effect against this bone loss.[9] APS achieves this by prohibiting the Receptor Activator of NF-κB Ligand (RANKL)-mediated differentiation of osteoclasts—the cells responsible for bone resorption—in cell culture experiments.[9] By regulating local osteoclastogenesis, Astragalus actively contributes to the maintenance of alveolar bone homeostasis.[9] Furthermore, Astragaloside IV (ASIV), a primary saponin, is well recognized for its anti-inflammatory and antioxidant properties, validating its protective role in managing systemic inflammatory diseases, a factor highly relevant given the systemic links of periodontitis.[5]

Molecular Signaling Intersections (NF-κB and MAPK pathways)

At the molecular level, Astragalus influences the master regulators of inflammation. Mechanistic investigations have confirmed that APS strongly suppresses the activation of Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-κB).[10] The NF-κB pathway is a crucial transcription factor controlling the expression of many pro-inflammatory genes. Additionally, APS down-regulates the phosphorylation of Extracellular signal-Regulated Kinases (ERK) and Jun N-terminal Kinases (JNK), key components of the Mitogen-Activated Protein Kinase (MAPK) pathways.[10] The inhibition of these combined pathways (MAPK and NF-κB) is central to controlling the cytokine production necessary for inflammation to progress.[10]

III. Mechanistic Profile of Gromwell (*L. erythrorhizon*) and Shikonin in Oral Microbiology

Gromwell root, traditionally known as Lithospermi Radix, provides the essential local defense against the microbial etiology of periodontal disease through its active constituent, Shikonin.

Primary Bioactive Constituents and Antimicrobial Potency

The primary active ingredients in *Lithospermum erythrorhizon* are naphthoquinones, primarily

Shikonin (SHI) and its derivatives (such as acetyl-shikonin and β-hydroxyisovaleryl-shikonin).[2] Shikonin is a powerful antimicrobial agent that exhibits pronounced inhibitory effects against key oral bacteria, including *Streptococcus mutans* and non-mutans streptococci.[14] Importantly, Shikonin dispersion has been demonstrated to inhibit not only the growth but also the crucial **biofilm formation** of *S. mutans*.[14] This anti-biofilm activity directly targets the dental plaque matrix, which is the physical structure underlying both gingivitis and periodontitis.

A small clinical trial further substantiated this local effect, showing that toothpaste containing Shikonin dispersion successfully decreased the measurable number of *S. mutans* in the oral cavity after one week of use.[14] This evidence confirms Gromwell's role as the primary local pathogen attacker, filling the need for direct microbial and anti-plaque control—a necessary prerequisite for the successful management of any periodontal disease.

Local Anti-inflammatory Action in Periodontal Tissues

While Astragalus manages the systemic and chronic inflammatory response, Shikonin also contributes substantial local anti-inflammatory benefits. Shikonin is known for its well-defined anti-inflammatory properties.[12] Research utilizing inflammation models in human periodontal ligament cells (hPDLCs) showed that Shikonin successfully reduced the expression of key inflammatory markers, including IL-1β, IL-6, and TNF-α.[12] This local action complements Astragalus's more diffuse anti-inflammatory role. Furthermore, Gromwell extract provides auxiliary benefits to oral tissue health by protecting against glycation and related oxidative stress.[15]

Impact on Alveolar Bone Regeneration

Gromwell's contribution extends beyond soft tissue and microbial control to include bone health. Shikonin derivatives are capable of enhancing bone mesenchymal stem cells and inhibiting osteoclast differentiation.[12] Crucially, the ethanol extract of *L. erythrorhizon* has been shown to actively promote osteoblastogenesis—the creation of new bone cells—through the positive regulation of the transcription factors Runx2 and Osterix.[17] This regenerative capacity suggests that Gromwell not only helps reduce inflammation but also actively stimulates periodontal tissue repair, adding significant value to the combined formulation.

IV. Synergistic Efficacy: The Combined Action of Astragalus and Gromwell Extracts

The power of combining *Astragalus* and *Gromwell* extracts lies in establishing a comprehensive, dual-axis therapeutic strategy that simultaneously addresses the microbial etiology and the destructive host-mediated consequences of periodontal disease.

The Complementary Therapeutic Strategy (Microbe vs. Host)

The combined formulation represents an optimized approach to periodontitis treatment: Gromwell provides the essential **Etiological Control** by deploying Shikonin's potent antimicrobial and anti-biofilm capabilities locally.[14] In parallel, Astragalus delivers **Host Response and Damage Mitigation** by modulating chronic cytokine signaling, inhibiting MMP activity, and maintaining alveolar bone stability.[6] By ensuring that the two most critical pathological pathways—microbial proliferation and uncontrolled host destruction—are attacked concurrently, the formulation maximizes therapeutic coverage across both gingivitis and established periodontitis.

The recognition of this complementary efficacy is reflected in commercial interest, specifically a patent application detailing a toothpaste composition that incorporates an herbal extract mixture of *Astragalus propinquus* and *Lithospermum erythrorhizon*. This composition is specifically claimed to ameliorate symptoms of periodontitis, bleeding gums, and tooth sensitivity.[18] Furthermore, traditional Korean medicine has historically utilized *A. membranaceus* in combination with *L. erythrorhizon* to leverage synergistic effects in various pathological conditions.[2]

Convergence on Core Inflammatory Signaling Pathways

A critical point of synergy occurs at the molecular level, particularly concerning the regulation of inflammation via the NF-κB pathway. Both Astragalus Polysaccharides (APS) and Shikonin are independently known to inhibit the NF-κB inflammatory cascade.[10] Simultaneous inhibition of this master inflammatory regulator by chemically distinct

compounds—APS being a large polysaccharide and Shikonin a small lipophilic naphthoquinone—is hypothesized to result in a highly potent, synergistic effect on pro-inflammatory cytokine production (IL-1β, TNF-α). Such dual targeting offers therapeutic robustness, potentially allowing for lower effective doses of each component while minimizing the risk of pathway escape or acquired cellular resistance often seen with single-agent inhibitors.

Synergistic Impact on Alveolar Bone Homeostasis

For advanced periodontitis, the primary therapeutic goal shifts to reversing the destructive process and promoting regeneration. Here, the synergistic effects of the two extracts are maximized. Astragalus provides necessary defense by inhibiting osteoclast differentiation through the RANKL pathway.[9] Concurrently, Gromwell not only shares some anti-osteoclast activity but also actively promotes osteoblastogenesis (new bone formation).[12] The resultant effect is a highly effective, balanced environment for bone maintenance, where bone resorption is blocked (Astragalus) and bone repair is stimulated (Gromwell).

The fundamental difference in their mechanistic strengths creates a highly comprehensive treatment profile, as summarized below:

Table 1: Complementary Mechanisms of Action Against Periodontal Disease

Extract Component	**Primary Bioactive(s)**	**Key Pathologies Targeted**	**Mechanistic Action/Targets**	**Supporting Data**
Astragalus (*A. propinquus*)	Polysaccharides (APS), Flavonoids (Quercetin, Kaempferol)	Chronic Inflammation, Host Immune Dysregulation, Alveolar Bone Loss	Downregulates IL-1β, TNF-α, IL-6; Inhibits NF-κB, MAPK; Suppresses Osteoclastogenesis (RANKL, MMPs)	[1]

Gromwell (*L. erythrorhizon*)	Naphthoquinones (Shikonin derivatives)	Microbial Biofilm, Local Inflammation, Anti-proliferation	Inhibits *S. mutans* and streptococci; Reduces IL-1β, IL-6, TNF-α in hPDLCs; Promotes Osteoblastogenesis	[12]

V. Formulation Science, Stability, and Safety Profile

Translating this synergistic efficacy into a viable oral care product requires overcoming significant formulation challenges specific to the lipophilic nature and chromatic properties of Shikonin.

Addressing Solubility and Stability Constraints

The clinical potential of Gromwell is often hampered by the physical characteristics of its active component. Shikonin and its naphthoquinone derivatives exhibit notoriously poor water solubility, making their effective incorporation into water-based oral gels or mouthwashes challenging.[14] Solutions employed in research include preparing a Shikonin dispersion solubilized by the inclusion of β-1,3-1,6 glucan, which successfully retains its antimicrobial efficacy.[14]

However, the synergistic combination offers a unique functional solution via the Astragalus component. Astragalus Polysaccharides (APS) possess self-assembly properties and function as natural macromolecular carriers.[19] APS has been shown to form stable complexes with lipophilic compounds, such as flavonoids, improving their gastrointestinal stability, solubility, and permeability.[19] The ability of APS to form complexes (sometimes at a 1:1 molar ratio with high association constants) suggests a chemical synergy where the Astragalus extract may act as a natural excipient to enhance the stability, dissolution, and residence time of the

poorly water-soluble Shikonin derivatives within the oral care formulation.[19]

Critical Formulation Constraint: Chromogenic Potential and Aesthetic Risk

A significant commercial and clinical barrier to the widespread use of Gromwell extract is its chromogenic property. Shikonin naphthoquinones are highly pigmented substances derived from the root of *L. erythrorhizon*.[13] The extract is a natural colorant whose appearance is dramatically influenced by pH.[21] At a low pH, the extract is typically red, but above pH 8.0, it transforms into a deep violet or purple color, often accompanied by polymerization.[21]

Since many commercially successful oral care products, particularly toothpastes, operate near neutral or slightly alkaline pH (to optimize fluoride efficacy or reduce enamel erosion), incorporating Shikonin risks yielding a dark purple product with a high potential for causing aesthetically unacceptable extrinsic dental staining.[21] Therefore, the commercial viability of this synergistic blend hinges entirely on sophisticated formulation engineering, requiring either strict, consistent pH maintenance (ideally in the slightly acidic range of pH 5.0–6.5) or highly effective targeted micro-encapsulation of Shikonin to isolate it from the aqueous matrix, preventing both polymerization and staining.

Table 2 provides a comparative analysis of the formulation barriers and solutions.

Table 2: Formulation and Commercial Feasibility Analysis

Challenge Area	Astragalus Solution/Contribution	Gromwell (Shikonin) Constraint	Critical Formulation Recommendation
Solubility & Bioavailability	APS acts as a natural macromolecular carrier to enhance solubility and stability of lipophilic components (flavonoids/potentially Shikonin).[19]	Poor water solubility requires specialized dispersion (e.g., β-glucan encapsulation).[14]	Utilize APS as a natural excipient while employing micro-encapsulation techniques (e.g., liposomes or dispersion) for Shikonin derivatives to maximize

			contact time.
Aesthetic Risk (Staining)	Generally colorless/pale extract; negligible aesthetic risk.	Highly pigmented naphthoquinones; color shifts from red to deep purple/violet above pH 8.0, posing a significant risk of extrinsic dental staining.[21]	Strict pH maintenance (below 8.0) is non-negotiable. Formulation must include pH buffers to stabilize the extract's color, even if compromising typical toothpaste alkalinity.
Systemic Safety/Interactions	Potential high-risk interactions (immunosuppressants, anticoagulants, autoimmune diseases) for systemic use.[24]	Favorable topical safety profile compared to synthetic antimicrobials.[26]	Target topical delivery only. Clinical vigilance required for high-concentration formulations in patients with underlying systemic conditions or those taking interacting medications.

Systemic Safety and Drug Interaction Assessment

For topical oral formulations, the systemic absorption of both extracts is generally considered low, mitigating many risks associated with high-dose oral supplementation.[27] Shikonin is reported to have a better safety profile than some common synthetic antimicrobial agents used in dentifrices, such as triclosan.[26]

However, the internal use of Astragalus carries several high-risk contraindications that must be considered if systemic absorption, even minimal, is a possibility in long-term, high-concentration applications.[24] Astragalus can enhance immune system activity, which may worsen symptoms in individuals with autoimmune diseases such as systemic lupus

erythematosus (SLE) or rheumatoid arthritis (RA).[24] Furthermore, Astragalus can interact with several classes of orthodox drugs: it may reduce the efficacy of immunosuppressants, increase the risk of bleeding when combined with blood thinners (like warfarin), and potentially decrease the excretion of lithium, leading to toxicity.[24] Clinical monitoring and clear patient warnings are essential, especially when developing specialized periodontal gels intended for localized application in patients with co-morbidities.

VI. Conclusion and Translational Recommendations

The combined application of *Astragalus propinquus* and *Lithospermum erythrorhizon* extracts provides a powerful, mechanistically complementary phytotherapeutic strategy for the treatment and prevention of periodontal disease. The evidence strongly supports a synergistic approach that controls both the microbial etiology and the destructive host-mediated immune response.

Summary of Mechanistic Synergy and Efficacy

The synergistic effect is rooted in the distinct yet convergent actions of the primary active compounds: Gromwell's Shikonin derivatives provide crucial local antimicrobial and anti-biofilm defense against pathogens like *S. mutans*.[14] Astragalus, through its polysaccharides and flavonoids, delivers comprehensive host modulation by reducing key pro-inflammatory cytokines (IL-1β, TNF-α) and inhibiting the progression toward alveolar bone loss via MMP and osteoclast suppression.[6] The molecular convergence on the NF-κB pathway, targeted by both agents, offers the strongest mechanistic basis for a synergistic anti-inflammatory outcome.[10]

Recommendations for Optimal Delivery Systems

Optimal delivery necessitates formulations that maximize contact time with the periodontal tissues; therefore, specialized periodontal gels or toothpastes are the preferred formats over rinse solutions.

1. **Chemical Engineering for Stability:** To address Shikonin's poor solubility, the

formulation should be engineered to utilize the potential functional synergy of Astragalus Polysaccharides (APS) as a natural macromolecular carrier to enhance the bioavailability of the lipophilic Shikonin derivatives.[19]

2. **Aesthetic Risk Mitigation (pH Mandate):** To overcome the critical commercial barrier of potential extrinsic staining, the final product must be strictly pH stabilized below 8.0. Maintaining the formulation in a slightly acidic range (e.g., pH 5.0–6.5) is mandatory to ensure the extract retains its red, non-staining hue, preventing the shift to a deep violet or purple chromogenic state.[21]

Future Research Directions and Requirements for Clinical Validation

While the mechanistic rationale is robust, clinical and pharmacological gaps remain:

1. **Quantification of Synergism:** Formal *in vitro* studies, ideally utilizing isobolographic analysis, are required to precisely quantify the synergistic anti-inflammatory and antimicrobial effects against primary periodontal pathogens, such as *Porphyromonas gingivalis* and *Tannerella forsythia*, extending the existing data beyond cariogenic streptococci.[14]
2. **Clinical Trials of Optimized Formulation:** The efficacy of the stable, aesthetically optimized combined formulation must be validated in human clinical trials. These trials must measure established indices such as Probing Pocket Depth (PPD), Clinical Attachment Loss (CAL), and specific gingivitis and plaque indices.[3]
3. **Absorption and Systemic Safety:** Further research into the rate and extent of systemic absorption of both Astragalus and Shikonin derivatives following prolonged topical use is necessary. This step is mandatory to conclusively assess safety in high-risk patient populations, such as those taking anticoagulants, immunosuppressants, or those diagnosed with autoimmune diseases.[24]

Works cited

1. Investigating the Mechanism of Astragalus in the Treatment of Periodontitis through Bioinformatics Analysis - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/378787461_Investigating_the_Mechanism_of_Astragalus_in_the_Treatment_of_Periodontitis_through_Bioinformatics_Analysis/fulltext/65e9ba6aadc608480a05ae3a/Investigating-the-Mechanism-of-Astragalus-in-the-Treatment-of-Periodontitis-through-Bioinformatics-Analysis.pdf
2. Protective Effect of a Mixture of Astragalus membranaceus and Lithospermum erythrorhizon Extract against Hepatic Steatosis in High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mice - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7106914/
3. Medicinal plants for gingivitis: a review of clinical trials - PMC - PubMed Central,

accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6281068/
4. Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/26916911/
5. In Vivo Insights into the Role of Astragaloside IV in Preventing and Treating Civilization Diseases: A Comprehensive Review - MDPI, accessed October 27, 2025, https://www.mdpi.com/1422-0067/26/9/4250
6. Astragalus membranaceus Extract Attenuates Inflammatory Cytokines and Matrix-Degrading Enzymes in Human Chondrocytes: A Novel Nutraceutical Strategy for Joint Health - MDPI, accessed October 27, 2025, https://www.mdpi.com/1467-3045/47/9/731
7. Beneficial Effects of Astragalus membranaceus (Fisch.) Bunge Extract in Controlling Inflammatory Response and Preventing Asthma Features - PMC, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10342042/
8. Investigating the Mechanism of Astragalus in the Treatment of Periodontitis through Bioinformatics Analysis - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/378787461_Investigating_the_Mechanism_of_Astragalus_in_the_Treatment_of_Periodontitis_through_Bioinformatics_Analysis
9. Astragalus polysaccharide alleviates alveolar bone destruction by regulating local osteoclastogenesis during periodontitis - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/34907709/
10. Inhibitory Effect of Astragalus Polysaccharides on Lipopolysaccharide-Induced TNF-α and IL-1β Production in THP-1 Cells - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6268450/
11. Progress on the Anti-Inflammatory Activity and Structure–Efficacy Relationship of Polysaccharides from Medical and Edible Homologous Traditional Chinese Medicines - MDPI, accessed October 27, 2025, https://www.mdpi.com/1420-3049/29/16/3852
12. Based on network pharmacology and molecular docking to explore the potential mechanism of shikonin in periodontitis - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11270799/
13. Cell-Specific Production and Antimicrobial Activity of Naphthoquinones in Roots of Lithospermum erythrorhizon - PMC, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC32117/
14. Inhibitory Effects of Shikonin Dispersion, an Extract of Lithospermum erythrorhizon Encapsulated in β-1,3-1,6 Glucan, on Streptococcus mutans and Non-Mutans Streptococci - MDPI, accessed October 27, 2025, https://www.mdpi.com/1422-0067/25/2/1075
15. Gromwell (Lithospermum erythrorhizon) root extract protects against glycation and related inflammatory and oxidative stress while offering UV absorption capability - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/29906314/
16. Gromwell (Lithospermum erythrorhizon) root extract protects against glycation and related inflammatory and oxidative stress while offering UV absorption

capability | Request PDF - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/325797483_Gromwell_Lithospermum_erythrorhizon_root_extract_protects_against_glycation_and_related_inflammatory_and_oxidative_stress_while_offering_UV_absorption_capability
17. Ethanol extract of Lithospermum erythrorhizon Sieb. et Zucc. promotes osteoblastogenesis through the regulation of Runx2 and Osterix - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/304402343_Ethanol_extract_of_Lithospermum_erythrorhizon_Sieb_et_Zucc_promotes_osteoblastogenesis_through_the_regulation_of_Runx2_and_Osterix
18. KR20200012181A - Toothpaste composition comprising herbal ..., accessed October 27, 2025, https://patents.google.com/patent/KR20200012181A/en
19. Oral absorption mechanisms of Astragalus polysaccharides and potential as an excipient to increase the absorption of flavonoids - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/395981243_Oral_absorption_mechanisms_of_Astragalus_polysaccharides_and_potential_as_an_excipient_to_increase_the_absorption_of_flavonoids
20. Effects of Astragalus polysaccharide on the solubility and stability of 15 flavonoids - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31712148/
21. US10532024B2 - Topical compositions of Lithospermum erythrorhizon (gromwell root) for treating or controlling excessive oil production in skin and minimizing glycation in skin, and methods of using the compositions - Google Patents, accessed October 27, 2025, https://patents.google.com/patent/US10532024B2/en
22. Novel chromogenic bacteria characterized and their probable treatment options using herbal products and reagents to restrict biofilm formation - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/319271103_Novel_chromogenic_bacteria_characterized_and_their_probable_treatment_options_using_herbal_products_and_reagents_to_restrict_biofilm_formation
23. Chromogenic bacterial staining of teeth: a scoping review - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11725193/
24. Astragalus - Special Subjects - MSD Manual Professional Edition, accessed October 27, 2025, https://www.msdmanuals.com/professional/special-subjects/dietary-supplements/astragalus
25. Astragalus | Memorial Sloan Kettering Cancer Center, accessed October 27, 2025, https://www.mskcc.org/cancer-care/integrative-medicine/herbs/astragalus
26. Long-term systemic toxicity of shikonin derivatives in Wistar rats - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/258312980_Long-term_systemic_toxicity_of_shikonin_derivatives_in_Wistar_rats
27. Astragalus | Nature's Way®, accessed October 27, 2025, https://naturesway.com/products/astragalus